2025 年 08 月 26 日 高端 PCB 设备卡位 AI 浪潮，技术生态壁垒赋能 国产替代与出海双线提速 —大族数控（301200.SZ）公司动态研究报告 买入(首次) 投资要点 | 分析师：尤少炜 | S1050525030002 | | --- | --- | | yousw@cfsc.com.cn | | | 基本数据 | 2 0 2 5-0 8-2 6 | 相关研究 ▌ AI 驱动 PCB 行业高景气，公司技术卡位核心设 备赛道 全球 AI 算力建设浪潮推动作为电子产品之母的 PCB 技术加速迭代与需 求扩容。2024 年全球 PCB 产业增长 5.8%，其中 18 层及以上高多层板 和 HDI 板市场营收分别跃升 40.2%和 18.8%，主要受 AI 服务器、高速 交换机等关键基础设施需求爆发驱动。消费电子市场复苏及汽车电子 技术升级进一步扩大电子产业终端需求。Prismark 预测未来五年 PCB 产业复合增长率可维持在 5.2%，高多层板及 HDI 板复合年增速分别高 达 15.7%和 6.4%。公司作为 PCB 专用设备龙头，匹配 AI 服务器、汽车 电子等高端领域需求，充分受益于下游 ...

8 月 20 日，公司披露 2025 年半年报，1H25 实现营业收入 57.0 亿元，同比+13.0%，归母净利润 6.6 亿元，同比+24.6%，毛利率 24.7%，同比+1.2pct；Q2 实现营业收入 31.9 亿元，同比+6.2%， 归母净利润 3.1 亿元，同比+0.9%，毛利率 21.6%，同比-0.8pct。 高压板块行业领先地位稳固，盈利能力持续提升。 1）网内：25H1 国网输变电设备招标 540.6 亿，同比增长 25%，公 司累计中标 44.6 亿元，同比+52%，市占率上升至 8.2%；②网外： 市场开拓显著，中标 3 家央企大客户框架，再次中标中广核项目， 实现 1000 千伏 GIL 网外市场首次应用。近期公司 GIL 厂房扩建项 目已完工，具备年生产 550 千伏 GIL 母线 100 公里以上的能力。 高压产品占比提升带动板块营收、盈利能力持续提升，25H1 公司 高压板块实现营收 32.6 亿元，同比+7.5%，实现毛利率 29.8%，同 比+2.2pct。 25 年电网投资维持高景气，公司订单储备充足。 25 年初国南网规划总投资超 8250 亿元，创历史新高。25H1 ...

Core Viewpoint - Tonghua Dongbao, a leading insulin manufacturer, reported a loss of approximately 42.72 million yuan in 2024, marking its first loss in nearly 20 years, attributed to a combination of legal issues, project terminations, and significant price reductions in insulin due to national procurement policies [1][3][8] Financial Performance - In 2024, Tonghua Dongbao achieved revenue of 2.01 billion yuan, a significant decline of 34.66% year-on-year [3] - The net profit attributable to shareholders was -42.72 million yuan, a decrease of 103.66% compared to the previous year [3][8] - The company's earnings forecast changed dramatically within three months, from an initial profit forecast of 40.53 million yuan to a confirmed loss [1][3] Legal Issues - The company lost a long-standing trademark infringement lawsuit against Ganli Pharmaceutical, resulting in a compensation payment of 61.31 million yuan [4][5] - The lawsuit, which began in 2011, concluded with a ruling that Tonghua Dongbao acted with "malice" in using the "Changshulin" trademark [4][5] R&D Challenges - The termination of the soluble insulin project led to impairment losses and prepayment losses totaling approximately 320 million yuan [3][6] - The decision to halt the project was influenced by the high costs of clinical trials and the competitive landscape, which diminished its commercial viability [6] Market Strategy - In response to national procurement policies, the company adopted a "price for volume" strategy, resulting in an average price reduction of 15% across its product line [7] - Despite the price cuts, the company's gross margin for biological products decreased by 5.92 percentage points [7] Future Outlook - In the first quarter of 2025, Tonghua Dongbao showed signs of recovery, with overseas revenue reaching 103 million yuan, a nearly 80% increase year-on-year [8] - The company is exploring international markets and has formed a strategic partnership with Jianyou Co. to enter the U.S. insulin market [8] - The company anticipates a net profit of approximately 21.7 million yuan for the first half of 2025, indicating a potential turnaround [8] R&D Investment - In 2024, the company invested 450 million yuan in R&D, a year-on-year increase of 7.15%, representing 22.42% of its revenue [8][9] - Currently, four products are in Phase III clinical trials, and three innovative drugs are in Phase II trials [9]

Core Insights - The company reported 1Q25 revenue of 86.6 billion yuan, an 18% year-on-year increase, exceeding expectations by 1.4% [1] - Adjusted net profit for 1Q25 was 10.95 billion yuan, surpassing expectations by 21%, driven by better-than-expected core local business operating profit and lower-than-expected losses from undistributed projects [1] - The adjusted net profit margin stood at 12.6% [1] Revenue Growth Trends - In 1Q25, core local business revenue grew 18% to 64.3 billion yuan, with takeaway orders expected to maintain a growth rate of nearly 10% and revenue increasing by 14% [1] - For 2Q25, takeaway order volume is projected to continue the same year-on-year growth rate, but revenue is expected to increase by only 5% due to subsidy impacts [1] - Instant retail segment saw a 32% growth in order volume in 1Q25, with expectations of maintaining this growth rate in 2Q25 following the launch of the "Meituan Flash Purchase" brand [1] - The in-store hotel and travel segment's gross transaction value (GTV) grew 30% in 1Q25, with a forecasted 28% growth in 2Q25 [1] Operating Profit Margin (OPM) Insights - Core local business operating profit increased by 39% to 13.49 billion yuan in 1Q25, exceeding expectations by 10%, with OPM rising from 17.8% to 21% [2] - However, 2Q25 operating profit margin for takeaway is expected to decline due to intensified industry competition and increased subsidy investments [2] - The in-store hotel and travel business's OPM is anticipated to slightly decrease in 2Q25 due to factors such as expansion into lower-tier cities and seasonal variations [2] New Business Developments - New business revenue grew 19% to 22.2 billion yuan in 1Q25, with operating losses narrowing to 2.27 billion yuan, better than expectations [3] - For 2Q25, new business revenue is projected to increase by 21% to 26.1 billion yuan, with expected operating losses rising to 2.6 billion yuan due to overseas investment [3] - The company plans to expand into more cities in Saudi Arabia and potentially enter the Brazilian market later in the year [3] Profit Forecast and Valuation - The company has lowered its adjusted net profit forecasts for 2025 and 2026 by 13% and 5% to 40.9 billion yuan and 54.1 billion yuan, respectively, due to increased subsidy pressures and overseas investments [3] - Despite these adjustments, the company maintains an outperform rating and a target price of 177 HKD, corresponding to 25/26 adjusted P/E ratios of 25/18 times [3] - Current stock price trades at 25/26 adjusted P/E ratios of 18/14 times [3]

Group 1: Research Basic Information - The research object is Qiaqia Food, belonging to the food and beverage industry, and the reception time was on May 16, 2025 [8] - The listed company's reception staff included the chairman and general manager Chen Xianbao, vice - chairman and deputy general manager Chen Qi, etc. [8] - Participating research institutions included Dongxing Securities, CITIC Securities, Tianfeng Securities, etc., as well as some fund management companies and asset management companies [2][9][10] Group 2: Core Views - The company's future development depends on product innovation and product strength, and each double - digit growth is accompanied by the emergence of a new large - scale product series [21] - The company aims to expand sales volume and increase gross profit margin through category innovation, product innovation, and channel sales service innovation, while continuously improving supply chain efficiency [17][19] Group 3: Specific Content Summaries Reasons for the decline in the company's first - quarter gross profit margin - The decline in the first - quarter gross profit margin was mainly due to the increase in sunflower seed raw material costs (affected by continuous rain in Inner Mongolia, the mold rate increased, and the output of qualified raw materials decreased, leading to price increases) and the increase in the purchase price of some nut raw materials. Product structure also had an impact [17] Scale and future plans of Sam's Club and snack retail channels - Sam's Club revenue increased by 50 - 60% last year, and the snack retail channel doubled. The company will increase investment in these channels this year [17] Plans for the third - largest product category - In the short - to - medium term, the company focuses on nuts and melon seeds. The third - largest category, such as peanuts, is in the incubation stage, and the company hopes to become a leading brand in this segment. The fresh - cut fries have achieved revenues of several million yuan in less than a year [17] Overseas development strategy for konjac products - The company first conducts trial sales overseas, leveraging its brand and channel advantages [17] Sales channels for Kui Zhen products - Kui Zhen is sold both online (e.g., its official flagship store) and offline (e.g., Sam's Club and RT - Mart's premium stores), and will continue to expand in these channels [19] Company's competitive points for nuts - The most important thing for products is quality, and for nuts, freshness must be ensured [19] Company's learning from Coca - Cola and农夫山泉 - These two companies are learning examples for Qiaqia Food in terms of products, channels, and brands. Qiaqia Food focuses more on product raw materials due to its high direct raw material cost ratio and is seeking a suitable model for itself [20] Company's view on KA direct - sales channels - The company pays attention to changes in offline retail channels, hopes that each link in the value chain can obtain reasonable profits, and will actively embrace the trend of KA direct - sales and explore a suitable cooperation model with distributors [20] Company's R & D considering population aging - The company has considered population aging in product R & D, such as nut powder products, and will develop specialized deep - processed products for the elderly. It has also launched low - GI nuts for people with sugar - control needs, and health is one of the future R & D directions [21]

Core Insights - SAIC Motor Corporation has accelerated its transformation results following comprehensive reforms implemented since 2024, as evidenced by its Q1 2025 performance [2][4] - The company achieved a total vehicle sales of 945,000 units in Q1 2025, marking a year-on-year increase of 13.3%, with total revenue reaching 140.86 billion yuan and a net profit of 3.02 billion yuan, up 11.4% [3][4] - SAIC's strategy includes a focus on its own brands, which accounted for over 60% of total sales, and a significant increase in sales of new energy vehicles [4][6] Financial Performance - In Q1 2025, SAIC reported total revenue of 140.86 billion yuan and a net profit of 3.02 billion yuan, with a non-recurring net profit of 2.85 billion yuan, reflecting a 34.4% year-on-year growth [3][4] - The company sold 945,000 vehicles in Q1 2025, with March sales reaching 386,000 units, a 1.14% increase year-on-year and a 30.8% increase month-on-month [3][4] Strategic Initiatives - SAIC has launched a new brand "SAIC尚界" in collaboration with Huawei, with an initial investment of 6 billion yuan to establish a dedicated team and factory [6][7] - The company is focusing on enhancing its global presence through a "Glocal" strategy, which combines global and local approaches to market expansion [7][8] - SAIC plans to introduce 17 new overseas models in the next three years, leveraging its market advantages to expand its international footprint [2][8] Product Development - The company is consolidating its chassis research and manufacturing capabilities to develop advanced control chassis technology, with the second generation expected to launch by 2027 [5] - SAIC's new energy vehicle sales reached 273,000 units in the first quarter of 2025, showing a nearly 30% year-on-year increase, with March sales exceeding 126,000 units, reflecting over 40% growth [3][4] Market Expansion - SAIC is deepening local partnerships in Southeast Asia and establishing KD factories, while also focusing on localized strategies in Latin America, the Middle East, and Africa [8] - The company emphasizes its commitment to becoming a global player, not just a Chinese automaker, by leveraging its early market advantages to expand its overseas operations [8]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 45.47, down 8% from previous estimates [1][8]. Core Insights - The company experienced a revenue decline of 5.09% in 2024, totaling RMB 7.57 billion, with a net profit attributable to shareholders of RMB 1.81 billion, down 24.63% [1][8]. - In Q1 2025, the company reported a revenue increase of 9.17% to RMB 2.44 billion, while net profit decreased by 5.26% to RMB 625 million [1][8]. - The EPS forecast for 2025 and 2026 has been lowered to RMB 1.98 and RMB 2.28, respectively, with a new forecast for 2027 set at RMB 2.64 [1][8]. Financial Summary - The company’s revenue for 2024 is projected at RMB 7.57 billion, with a net profit of RMB 1.81 billion and a recurring net profit of RMB 1.39 billion [2]. - The revenue growth rates for the upcoming years are expected to be 11.9% in 2025, 13.2% in 2026, and 12.9% in 2027 [2]. - The net profit attributable to shareholders is expected to recover to RMB 1.98 billion in 2025, with a growth of 9.8% [2]. Business Performance - The respiratory solutions segment saw a revenue decline of 22.42% in 2024, totaling RMB 2.60 billion, primarily due to high base effects from 2023 [4][9]. - The glucose management and POCT solutions segment experienced significant growth, with revenue increasing by 40.20% to RMB 1.03 billion in 2024 [10]. - The company’s export revenue reached RMB 949 million in 2024, marking a year-on-year increase of 30.42%, supported by strategic investments and enhanced overseas channels [11].

Core Insights - Yongshun Bio achieved operating revenue of 269 million yuan and net profit of 40 million yuan in 2024, maintaining a steady operational trend [1] - The company has successfully expanded its overseas revenue, surpassing 20 million yuan for the first time [1] - In Q1 2025, Yongshun Bio reported operating revenue of 65.46 million yuan and net profit attributable to shareholders of 7.92 million yuan, continuing its stable performance [1] Product and Market Position - Yongshun Bio is a leading domestic veterinary biological product company, focusing on swine and poultry vaccines with over 30 product varieties [2] - The company holds a strong market position in core products, with significant market shares in swine vaccines, particularly the classical swine fever live vaccine and the three-in-one vaccine for swine [2] - Key products such as the pseudorabies live vaccine and the porcine circovirus type 2 inactivated vaccine saw substantial sales growth, with revenues of 14.91 million yuan (up 35.47%) and 8.12 million yuan (up 71.71%) respectively in 2024 [2] Financial and Operational Efficiency - Yongshun Bio has optimized its financial structure, reducing total liabilities by 16.35% compared to the beginning of the year, enhancing its balance sheet [2] - The company invested 23 million yuan in R&D in 2024, accounting for 8.54% of its operating revenue, and obtained new drug registration certificates and patents, enriching its product line [3] - The production system has undergone technological innovation and management upgrades, with successful GMP dynamic acceptance of its bacterial inactivated vaccine production line [3] International Expansion - Yongshun Bio has successfully registered new products in Egypt, adding to its international presence alongside Vietnam, with a total of 7 and 2 products registered in these countries respectively [4] - The company’s overseas revenue reached over 20 million yuan in 2024, marking a year-on-year growth of 34.31%, indicating an increasing contribution from international markets [4]

Group 1 - The core viewpoint emphasizes the optimistic outlook for platform enterprises driven by a diverse product matrix, with domestic substitution and overseas expansion as dual engines of growth [1][4] Group 2 - The investment rating is maintained at "Buy," with a downward adjustment of EPS for 2025 and 2026 to 0.77 and 0.93 yuan respectively, and a new EPS for 2027 set at 1.11 yuan. The target price is set at 19.25 yuan based on a 25x PE valuation for 2025 [2] - In 2024, the company is projected to achieve a revenue of 4.047 billion yuan, a year-on-year increase of 4.86%, and a net profit of 581 million yuan, a year-on-year increase of 7.05% [2] - The revenue for Q4 2024 is expected to be 1.08 billion yuan, with a year-on-year increase of 0.78% and a quarter-on-quarter increase of 6.67% [2] Group 3 - The diverse product matrix for platform enterprises includes significant revenue growth in electronic materials, catalytic materials, biomedical, new energy materials, and precision ceramics, with respective year-on-year growth rates of 4.22%, 10.01%, 6.53%, 48.34%, and 41.68% [3] - The company is focusing on domestic substitution and overseas expansion, particularly in the ceramic carrier market, where it aims to ensure supply chain security and cost reduction for domestic manufacturers [3] - The biomedical sector is expected to benefit from a red-chip structure that will facilitate overseas business expansion, with a focus on seven major sales regions including the Middle East, North Africa, Southeast Asia, and Europe [4]

| 投资要点 | | --- | 公告要点： 公司公布2024年年报，业绩超我们预期。2024年全年公司营业收入99.37亿元，同比+33.0%， 归母净利润12.09亿元，同比+35.6%，扣非归母净利润11.13亿元，同比+30.2%。其中2024Q4公 司 实 现 营 收 33.58 亿 元 ， 同 环 比 +41.8%/+28.8%； 实 现 归 母 净 利 润 4.31 亿 元 ， 同 环 比 +45.3%/+34.4%；实现扣非归母净利润4.04亿元，同环比+28.9%/+40.6%。 重点客户需求放量，线控制动及轻量化产品快速增长： 公司核心客户奇瑞汽车/吉利汽车2024年产量同比+38%/+30%，驱动公司业绩增长。分子公司 看，24年伯特利电子收入14.7亿元，同比+47%，威海伯特利收入18.7亿，同比+37%。 墨西哥产值提升压制整体毛利率，线控制动及机械转向业务盈利中枢提升： 2024年毛利率21.14%，同比-1.4pct，主要为墨西哥工厂尚处于爬坡期所致。分子公司：24年伯 特利电子净利率11%，同比+5.4pct，线控制动盈利提升明显；威海伯特利净利率13%，同 比-4.5pct ...